Page last updated: 2024-11-10

orientin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

orientin: structure given in first source; RN given refers to the (D-glucopyranosyl)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

orientin : A C-glycosyl compound that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5281675
CHEMBL ID520866
CHEBI ID7781
SCHEMBL ID25942
MeSH IDM0180982

Synonyms (73)

Synonym
nsc-133101
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-8-beta-d-glucopyranosyl-5,7-dihydroxy-
orientin (flavone)
luteolin 8-glucoside
2-(3,4-dihydroxyphenyl)-8-beta-d-glucopyranosyl-5,7-dihydroxy-4h-1-benzopyran-4-one
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-8-.beta.-d-glucopyranosyl-5,7-dihydroxy-
8-beta-d-glucosylluteolin
CHEBI:7781 ,
lutexin
2-(3,4-dihydroxyphenyl)-8-beta-d-glucopyranosyl-5,7-dihydroxy-4h-chromen-4-one
28608-75-5
orientin
luteolin 8-c-glucoside
C10114 ,
CHEMBL520866
luteolin 8-c-beta-d-glucopyranoside
8-beta-d-glucopyranosyl-3',4',5,7-tetrahydroxyflavone
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
A819507
unii-iax93xcw6c
luteolin-8-glucoside
iax93xcw6c ,
bdbm84982
S9099
luteolin-8-c-glucoside
AKOS015896746
SCHEMBL25942
8-glucosylluteolin
8c-hexosyl luteolin
AC-34280
Q-100362
luteolin 8-c-.beta.-glucopyranoside
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-(.beta.-d-glucopyranosyl)-4h-1-benzopyran-4-one
orientine
massbank pr020063
8-.beta.-d-glucopyranosyl-3',4',5,7-tetrahydroxyflavone
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-((2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)-4h-chromen-4-one
2-(3,4-dihydroxyphenyl)-8-.beta.-d-glucopyranosyl-5,7-dihydroxy-4h-chromen-4-one
luteolin 8-c-.beta.-d-glucopyranoside
niaid aids# 026706
8-.beta.-d-glucosylluteolin
8-(.beta.-d-glucopyranosyl)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4h-1-benzopyran-4-one
d-glucitol, 1,5-anhydro-1-c-(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4h-1-benzopyran-8-yl)-, (1s)-
j17.734b ,
2-(3,4-dihydroxyphenyl)-8-.beta.-d-glucopyranosyl-5,7-dihydroxy-4h-1-benzopyran-4-one
(1s)-1,5-anhydro-1-(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4h-chromen-8-yl)-d-glucitol
mfcd00017432
DTXSID60182790 ,
orientin, analytical standard
orientin, primary pharmaceutical reference standard
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-4h-chromen-4-one
AS-73888
dtxcid00105281
luteolin 8-c-beta-glucopyranoside
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-8-(beta-d-glucopyranosyl)-4h-1-benzopyran-4-one
8-(beta-d-glucopyranosyl)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4h-1-benzopyran-4-one
orientin, >=97% (hplc)
Q421676
HY-N0405
PLAPMLGJVGLZOV-VPRICQMDSA-N
HMS3886J16
CCG-269214
CS-0008937
NCGC00482848-01
4h-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-8-beta-d-glucopyranosyl-5,7-dihydroxy
orientin 100 microg/ml in acetonitrile:water
USE ,
EN300-19631775
GLXC-13194
luteolin 8-c-b-d-glucopyranoside
8-b-d-glucopyranosyl-3',4',7'-tetrahydroxyflavone
O0503

Research Excerpts

Overview

Orientin is a naturally occurring bioactive flavonoid. It has diverse biological properties, including anti-inflammation, anti-oxidative, and anti-tumor, and cardio protection.

ExcerptReferenceRelevance
"Orientin is a flavone isolated from medicinal plants used in traditional Chinese medicine (TCM) that suppresses the growth of cancer cells in vitro. "( Orientin regulates the proliferation and migration of hepatocellular carcinoma cells.
Dong, BZ; Li, J; Liu, YM; Tao, JY; Wan, L; Wan, LP; Yi, ML; Yu, YJ, 2023
)
3.8
"Orientin is a flavonoid C-glycoside that has repeatedly been shown to have pharmacological effects in the past decades."( Orientin Reduces the Effects of Repeated Procedural Neonatal Pain in Adulthood: Network Pharmacology Analysis, Molecular Docking Analysis, and Experimental Validation.
Guo, DD; Huang, HY; Liu, HE; Liu, K; Luo, XJ, 2023
)
3.07
"Orientin is a naturally occurring bioactive flavonoid that possesses diverse biological properties, including anti-inflammation, anti-oxidative, anti-tumor, and cardio protection."( Inhibitory effects of orientin in mast cell-mediated allergic inflammation.
Choi, JK; Dhakal, H; Khang, D; Kim, SH; Kwon, TK; Lee, S, 2020
)
1.59

Effects

Orientin has extensive pharmaceutical effects of antioxidant, anti-inflammatory, antithrombosis, antiapoptosis, and so on. Orientin has been known to have anxiolytic and antioxidative activities.

ExcerptReferenceRelevance
"Orientin has been reported to have extensive pharmaceutical effects of antioxidant, anti-inflammatory, antithrombosis, antiapoptosis, and so on. "( Orientin Attenuates Cerebral Ischemia/Reperfusion Injury in Rat Model through the AQP-4 and TLR4/NF-κB/TNF-α Signaling Pathway.
An, F; An, Z; Wang, S; Wang, X, 2017
)
3.34
"Orientin has been known to have anxiolytic and antioxidative activities."( Orientin inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis.
Bae, JS; Ku, SK; Lee, T; Yoo, H, 2014
)
2.57

Treatment

Orientin treatment attenuated the oxidative stress markers and increased the concentrations of serotonin and norepinephrine in the hippocampus and prefrontal cortex of CUMS mice. Post-treatment orientin was found to suppress LPS-mediated release of HMGB1 andHMGB1-mediated cytoskeletal rearrangements.

ExcerptReferenceRelevance
"Orientin treatment attenuated the oxidative stress markers and increased the concentrations of serotonin and norepinephrine in the hippocampus and prefrontal cortex of CUMS mice."( Orientin improves depression-like behavior and BDNF in chronic stressed mice.
Huang, XF; Lan, N; Liu, Y; Ren, J; Wang, ST; Wu, Y; Yu, Y, 2015
)
2.58
"Post-treatment orientin was found to suppress LPS-mediated release of HMGB1 and HMGB1-mediated cytoskeletal rearrangements."( Orientin inhibits HMGB1-induced inflammatory responses in HUVECs and in murine polymicrobial sepsis.
Bae, JS; Ku, SK; Lee, T; Yoo, H, 2014
)
2.18

Pharmacokinetics

ExcerptReferenceRelevance
" This validated method was successfully applied to a pharmacokinetic study in rabbits after the intravenous administrations of orientin and TRO PE at three different doses."( Determination and pharmacokinetics of orientin in rabbit plasma by liquid chromatography after intravenous administration of orientin and Trollius chinensis Bunge extract.
Huo, T; Li, F; Li, X; Lu, X; Qin, F, 2007
)
0.82
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
C-glycosyl compoundA glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond.
tetrahydroxyflavoneAny hydroxyflavone carrying four hydroxy substituents.
3'-hydroxyflavonoidAny hydroxyflavone with a hydroxy substituent at position 3'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mitogen-activated protein kinase 10Homo sapiens (human)IC50 (µMol)46.95000.00201.703510.0000AID1799639
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)46.95000.00010.72667.8000AID1799639
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (72)

Processvia Protein(s)Taxonomy
protein phosphorylationMitogen-activated protein kinase 10Homo sapiens (human)
signal transductionMitogen-activated protein kinase 10Homo sapiens (human)
JNK cascadeMitogen-activated protein kinase 10Homo sapiens (human)
response to light stimulusMitogen-activated protein kinase 10Homo sapiens (human)
Fc-epsilon receptor signaling pathwayMitogen-activated protein kinase 10Homo sapiens (human)
regulation of circadian rhythmMitogen-activated protein kinase 10Homo sapiens (human)
rhythmic processMitogen-activated protein kinase 10Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 10Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
JUN kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein bindingMitogen-activated protein kinase 10Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 10Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 10Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
nucleoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 10Homo sapiens (human)
plasma membraneMitogen-activated protein kinase 10Homo sapiens (human)
nucleusMitogen-activated protein kinase 10Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 10Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1859366Displacement of [3H]TTP/polyA from HIV-1 reverse transcriptase at 200 ug/ml relative to control2022European journal of medicinal chemistry, Apr-05, Volume: 233Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs.
AID338974Inhibition of cow milk xanthine oxidase at 50 ug/mL
AID404008Cytotoxicity against human KB cells
AID1253021Inhibition of LPS-induced neutrophil migration in HUVEC cells for 6 hrs pretreated with LPS for 4 hrs2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Caffeoyl glucosides from Nandina domestica inhibit LPS-induced endothelial inflammatory responses.
AID1253019Inhibition of LPS-induced neutrophil adhesion in HUVEC cells assessed as neutrophil adhesion to cell monolayer at 20 uM for 6 hrs pretreated with LPS for 4 hrs by fluorescence microplate reader assay (Rvb = 86%)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Caffeoyl glucosides from Nandina domestica inhibit LPS-induced endothelial inflammatory responses.
AID1236855Retention time of the compound by HPLC-SPE-NMR analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Acylated glucosylflavones as α-glucosidase inhibitors from Tinospora crispa leaf.
AID1705065Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoi2020European journal of medicinal chemistry, Dec-15, Volume: 208Unraveling the anti-influenza effect of flavonoids: Experimental validation of luteolin and its congeners as potent influenza endonuclease inhibitors.
AID474220Cytotoxicity against human HMC1 cells assessed induction of morphological changes at 50 uM2010Bioorganic & medicinal chemistry letters, Apr-01, Volume: 20, Issue:7
New inhibitors for expression of IgE receptor on human mast cell.
AID1368908Cytotoxicity against human A2780 cells assessed as reduction in cell viability at 5 to 100 uM incubated for 24 hrs by MTT assay2018Bioorganic & medicinal chemistry letters, 01-15, Volume: 28, Issue:2
(-)-9'-O-(α-l-Rhamnopyranosyl)lyoniresinol from Lespedeza cuneata suppresses ovarian cancer cell proliferation through induction of apoptosis.
AID1253022Inhibition of LPS-induced neutrophil migration in HUVEC cells assessed as migration index at 20 uM for 6 hrs pretreated with LPS for 4 hrs (Rvb = 155 No_unit)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Caffeoyl glucosides from Nandina domestica inhibit LPS-induced endothelial inflammatory responses.
AID1253016Inhibition of LPS-induced hyperpermeability in HUVEC cells assessed as permeability at 20 uM for 6 hrs pretreated with LPS for 4 hrs by evans blue dye flux based immunofluorescence analysis (Rvb = 100%)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Caffeoyl glucosides from Nandina domestica inhibit LPS-induced endothelial inflammatory responses.
AID456317Antioxidant activity assessed as trolox equivalent by TEAC assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
Reliability of bond dissociation enthalpy calculated by the PM6 method and experimental TEAC values in antiradical QSAR of flavonoids.
AID1799639Kinase Assay from Article 10.1002/cbic.201000487: \\Biological evaluation and structural determinants of p38u00CEu00B1 mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.\\2010Chembiochem : a European journal of chemical biology, Dec-10, Volume: 11, Issue:18
Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (125)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (1.60)18.7374
1990's4 (3.20)18.2507
2000's21 (16.80)29.6817
2010's70 (56.00)24.3611
2020's28 (22.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.82 (24.57)
Research Supply Index4.93 (2.92)
Research Growth Index5.43 (4.65)
Search Engine Demand Index58.64 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.19%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other134 (97.81%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]